window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 2 clinical trial

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    MediciNova completes patient enrollment in Phase 2 neuropathy prevention study

    MediciNova has completed patient enrollment in a Phase 2 clinical [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AmacaThera signs exclusive global licensing agreement with Pacira Biosciences for up to $230 million

    AmacaThera has entered an exclusive worldwide licensing agreement with Pacira [...]

    May 5, 2026
  • Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Levicept to present Phase 2 LEVI-04 data showing bone marrow lesion and pain reduction at ACR Convergence 2025

    Levicept Ltd will present new findings from its Phase 2 [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Acella Pharmaceuticals reports positive Phase 2 results for North Star desiccated thyroid extract

    Acella Pharmaceuticals and Neuvosyn Laboratories have reported positive topline results [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    First-in-class cell therapy for rare mitochondrial disorder gains FDA fast track

    FDA recognition accelerates development of first-in-class mitochondrial cell therapy for [...]

    May 5, 2026
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Calla Lily selected for $50M Wellcome Leap antibiotic programme
    Categories: Drug Delivery & Formulation, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine
    Categories: Advanced Therapies, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Alamar expands Alzheimer’s proteomics partnership with 86,000 more samples
    Categories: Central Nervous System, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top